Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 16 May, 2014 and appeared in  DietCardiovascularObesityType 2 DiabetesIssue 729

The Potential of Low-Carbohydrate Diets to Reduce CVD Risk

Consuming low-carbohydrate diets can reduce inflammation in patients with type 2 diabetes which may decrease the risk of patients developing cardiovascular disease.... 

Advertisement

According to a Swedish study, eating a low-carbohydrate diet can reduce inflammation in patients with type 2 diabetes. People with type 2 diabetes have a higher level of inflammation than those without diabetes, and this may play a part in the increased risk of cardiovascular disease associated with diabetes. The Linkoping University study included 61 participants with type 2 diabetes. The participants were randomly divided up and given either a low-carbohydrate or low-fat diet. The study method was a retrospective follow-up. The low-carbohydrate diet and the low-fat diet were compared over the course of 2 years. Additionally, the researchers studied how the diets impacted inflammation by checking the inflammation levels in the blood of each patient.

The results showed that both the low-carbohydrate and low-fat diets helped participants lose weight, roughly around nine pounds, but when it came to which diet produced reduced inflammatory markers in the blood, the low-carbohydrate diet succeeded. Additionally, glucose-levels dropped more in the low-carbohydrate diet groups. The researchers recommended with respect to the cardiovascular risk involved, aiming carbohydrate energy intake to 20% as a treatment alternative for at-risk patients.

Practice Pearls:
  • Low-carbohydrate diets help aid in weight loss as well as reduce inflammatory markers in the blood, and drop glucose-levels
  • Reducing inflammation in patients with type 2 diabetes may have potential to decrease the risk of patients developing cardiovascular diseases in the future
  • With respect to the cardiovascular risk involved, aim carbohydrate energy intake to 20%, which can be established as a treatment alternative

Diabetologia. 2012 Aug;55(8):2118-27. doi: 10.1007/s00125-012-2567-4. Epub 2012 May 6

  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  DietCardiovascularObesityType 2 DiabetesIssue 729

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014
Peripheral Neuropathy Associated with CV Disease and Stroke in Type 2 Diabetes Patients
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control